Lilly eying deal with Turkish drug company
Eli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, sources say.
Health Care Businesses
Articles
Eli Lilly unit plans to buy feed-enzyme maker
Drugmaker Eli Lilly and Co.'s Elanco animal health division plans to buy a privately held maker of feed-enzyme products that improve poultry, egg and meat production.
French breast-implant recall could sway U.S. device debate
U.S. medical device makers have spent the last year urging government officials to approve high-risk products faster, like their European counterparts. A scandal over leaking breast implants made in France, however, may make the argument more difficult.
Lilly’s Zyprexa pact with health providers wins approval
Eli Lilly and Co. has won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper marketing of the company's best-selling medication, Zyprexa, raised their costs.
Once-rising star AIT Laboratories now cutting jobs
AIT Laboratories, one of the area’s fastest-growing companies in recent years, confirmed Tuesday that it is eliminating jobs, but would not say how many. The company said it is restructuring.
Boston lawsuit claims DES-breast cancer link
Fifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES for millions of pregnant women from about 1938 to the early 1970s.
Healthx receives $22M capital infusion
Frontier Capital in Charlotte, N.C., provided the funding that will support the continued expansion of Healthx, a local provider of online health care portals.
Lilly challenging Biogen patent in London lawsuit
Eli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system diseases.
Lilly’s 2012 earnings forecast misses analyst estimates
Indianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a wide margin, sending shares down.
Walgreen expects to lose most Express Scripts biz
Drugstore operator Walgreen Co. said Thursday it expects to lose almost 90 percent of prescriptions handled by pharmacy benefits manager Express Scripts Inc. after it leaves Express Scripts' networks on Jan. 1.
Franciscan group picked for model accountable care program
The Indianapolis-based partnership is among 32 in the U.S. chosen for a model program designed to provide more coordinated care for people served by Medicare.
Endocyte shares plunge on clinical trial results
Shares of Endocyte Inc. plummeted more than 60 percent Tuesday morning after clinical trial results showed the company’s experimental ovarian cancer drug led to shorter survival times than treatment with a standard cancer drug.
Lilly shares rise on possibility for Alzheimer’s drug
Eli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s experimental Alzheimer’s drug could double the share price.
Q&A
Carmel resident David Wasilewski has launched WhatNext, a website that uses algorithms to make it easier for cancer patients to connect with others in similar circumstances. Wasilewski, 39, spent eight years as chief operating officer of the Spanx line of body shapers and did health care consulting before that. In addition to helping patients, he thinks WhatNext can become a way for health care organizations share their expertise with patients in need.
Takeda, Lilly may face thousands of suits over Actos claims
Takeda Pharmaceutical Co. and marketing co-partner Eli Lilly and Co. may face as many as 10,000 lawsuits in U.S. courts over allegations that their Actos diabetes drug causes bladder cancer.
WellPoint won’t put brand-name Lipitor on generics list
Indianapolis-based WellPoint Inc., the largest U.S. health insurer by enrollment, will favor a copy of the blockbuster cholesterol medication made by Watson Pharmaceuticals Inc., the insurer said.
Drugmakers, pharmacists at odds
Indianapolis-based Eli Lilly and Co. recently rejected CVS Caremark’s demands for big price discounts on its insulins, leading CVS to kick Lilly’s insulins off its list of recommended drugs.
Decatur Vein Clinic branches out
In little more than a decade, former Conseco director Dr. David Decatur has turned his single-office family practice into a multistate chain of vein clinics. A 14th location is planned.
UnitedHealth to acquire Medicare insurer XLHealth
UnitedHealth Group Inc. said it will acquire XLHealth Corp., a provider of managed care for chronically ill Medicare members. Indianapolis-based WellPoint Inc. had been considering a possible acquisition of the company.
Potential Lilly drug doubles good cholesterol
Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.